儿童舒更葡糖使用决策及剂量相关因素:回顾性横断面观察研究
基于MPOG数据库97,654例0-17岁儿童全麻气管插管并罗库溴铵/维库溴铵维持的病例,47.1%使用舒更葡糖,43.1%使用新斯的明,9.8%未拮抗。使用舒更葡糖的变异主要归于机构(40.4%)和主治麻醉医师(27.1%);年轻年龄、较高ASA分级、神经肌肉疾病、心脏手术、拮抗前1小时内较高神经肌肉阻滞剂剂量及较短手术时间与舒更葡糖使用相关。
要点
- 儿童舒更葡糖使用率47.1%,新斯的明43.1%,未拮抗9.8%。
- 使用决策变异主要归于机构(40.4%)和主治麻醉医师(27.1%)。
- 年轻年龄、高ASA分级、心脏手术及较高肌松剂剂量与舒更葡糖使用相关。
核心结论
- 舒更葡糖使用变异主要归因于机构和主治麻醉医师。
- 与舒更葡糖使用相关的患者因素包括年轻年龄、较高肌松剂剂量和较高医疗复杂度。
研究设计与样本
- 回顾性横断面观察研究,使用MPOG数据库EHR登记数据。
- 纳入2016年1月1日至2020年12月31日美国医院0-17岁儿童全麻气管插管并罗库溴铵或维库溴铵病例,共97,654例,来自30家机构。
- 采用广义线性混合模型(机构和麻醉医师随机截距)及组内相关系数分析。
主要发现
- 47.1%接受舒更葡糖,43.1%接受新斯的明,9.8%未接受拮抗剂。
- 舒更葡糖选择变异归因于机构40.4%、主治麻醉医师27.1%。
- 与舒更葡糖使用(对比新斯的明)相关因素:机构首次使用后时间(每月OR 1.08,95%CI 1.08-1.09,P<.001);0-27天OR 2.59(2.00-3.34),28天-1岁OR 2.72(2.16-3.43),对比12-17岁,P<.001;ASA III OR 1.32(1.23-1.42),ASA IV OR 1.71(1.46-2.00),对比ASA I,P<.001;神经肌肉疾病OR 1.14(1.04-1.26),P=.006;心脏手术OR 1.76(1.40-2.22),P<.001;拮抗前1小时内肌松剂>2 ED95s/kg OR 4.58(4.14-5.07),对比无,P<.001;手术时间<60分钟OR 2.06(1.75-2.43),对比>300分钟,P<.001。
临床怎么用
- 儿童舒更葡糖使用存在显著机构与医师间差异,提示需标准化决策。
- 对年轻、高ASA分级、心脏手术或深阻滞患儿可考虑舒更葡糖拮抗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sugammadex was initially approved for reversal of neuromuscular blockade in adults in the United States in 2015. Limited data suggest sugammadex is widely used in pediatric anesthesia practice however the factors influencing use are not known. We explore patient, surgical, and institutional factors associated with the decision to use sugammadex versus neostigmine or no reversal, and the decision to use 2 mg/kg vs 4 mg/kg dosing. METHODS: Using data from the Multicenter Perioperative Outcomes Group (MPOG) database, an EHR-derived registry, we conducted a retrospective cross-sectional study. Eligible cases were performed between January 1, 2016 and December 31, 2020, for children 0 to 17 years at US hospitals. Cases involved general anesthesia with endotracheal intubation and administration of rocuronium or vecuronium. Using generalized linear mixed models with institution and anesthesiologist-specific random intercepts, we measured the importance of a variety of patient, clinician, institution, anesthetic, and surgical risk factors in the decision to use sugammadex versus neostigmine, and the decision to use a 2 mg/kg vs 4 mg/kg dose. We then used intraclass correlation statistics to evaluate the proportion of variance contributed by institution and anesthesiologist specifically. RESULTS: There were 97,654 eligible anesthetics across 30 institutions. Of these 47.1% received sugammadex, 43.1% received neostigmine, and 9.8% received no reversal agent. Variability in the choice to use sugammadex was attributable primarily to institution (40.4%) and attending anesthesiologist (27.1%). Factors associated with sugammadex use (compared to neostigmine) include time from first institutional use of sugammadex (odds ratio [OR], 1.08, 95% confidence interval [CI], 1.08-1.09, per month, P < .001), younger patient age groups (0-27 days OR, 2.59 [2.00-3.34], P < .001; 28 days-1 year OR, 2.72 [2.16-3.43], P < .001 vs 12-17 years), increased American Society of Anesthesiologists [ASA] physical status (ASA III: OR, 1.32 [1.23-1.42], P < .001 ASA IV OR, 1.71 [1.46-2.00], P < .001 vs ASA I), neuromuscular disease (OR, 1.14 (1.04-1.26], P = .006), cardiac surgery (OR, 1.76 [1.40-2.22], P < .001), dose of neuromuscular blockade within the hour before reversal (>2 ED95s/kg OR, 4.58 (4.14-5.07], P < .001 vs none), and shorter case duration (case duration <60 minutes OR, 2.06 [1.75-2.43], P < .001 vs >300 minutes). CONCLUSIONS: Variation in sugammadex use was primarily explained by institution and attending anesthesiologist. Patient factors associated with the decision to use sugammadex included younger age, higher doses of neuromuscular blocking agents, and increased medical complexity.
引用
- Brown SES, Mentz G, Cassidy R, et al. Factors Associated With Decision to Use and Dosing of Sugammadex in Children: A Retrospective Cross-Sectional Observational Study. Anesth Analg. 2024. PMID: 39688966. doi:10.1213/ANE.0000000000006831
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。